Nanobiotix announces license agreement with Janssen for development and commercialisation of new cancer treatment
Betsy Goodfellow | July 10, 2023 | News story | Sales and Marketing | Cancer, Janssen, License Agreement, Oncology, nanobiotix
Nanobiotix has announced a global licensing, co-development and commercialisation agreement with Janssen Pharmaceutica NV, one of the Janssen Pharmaceutical Companies of Johnson & Johnson. The agreement is for the investigational, potential first-in-class radioenhancer NBTXR3.
NBTXR3 is currently in several studies assessing its safety and efficacy, including the global phase 3 NANORAY-312 study which is evaluating the treatment for patients with locally advanced head and neck cancer. NBTXR3 is also being assessed for its potential as a systemic agent in combination with anti-PD-1 immune checkpoint inhibitors for the treatment of metastatic cancers.
Under the terms of the agreement, Nanobiotix will grant Janssen a worldwide license for the development and commercialisation of NBTXR3, in collaboration with the Interventional Oncology R&D Unit of Johnson & Johnson. Nanobiotix will receive near-term cash and operational support valued up to $60m, including an upfront cash licensing fee of $30m and regulatory and development support for study NANORAY-312 up to $30m, provided at Janssen’s discretion.
Laurent Levy, chairman of Nanobiotix’s executive board, commented: “As pioneers in the field of nanotherapeutics for the past 20 years, we knew that the true impact of our innovation in oncology would be in its potential to reach millions of patients around the world. For that, we needed to find the right partner, at the right time, with proven global development and commercialisation capabilities. We are delighted to collaborate with Janssen as we aim to improve the lives of patients with cancer around the world.”
Bart van Rhijn, Nanobiotix’s chief financial officer, added: “We expect this agreement, and the collaboration it enables, to further drive the expansion of NBTXR3 development and accelerate the realisation of its promise for patients in need. We look forward to maximising the value of NBTXR3 for our global stakeholders.”
Betsy Goodfellow
Related Content
Central nervous system cancer metastases – the evolution of diagnostics and treatment
The current forms of immunotherapy, how T cell therapy works and what the future holds
BioMed X and Servier launch Europe’s first XSeed Labs to advance AI-powered antibody design
BioMed X and Servier have announced the launch of Europe’s first XSeed Labs research project, …
T-cell therapy – the evolution of cancer treatments
The current forms of immunotherapy, how T cell therapy works and what the future holds
